Month: August 2025

Basic data about the CompanyUAB „Orkela“ (hereinafter – the Company) is a private limited liability company registered with the State Enterprise Centre of Registers on 24 September 2015.Legal address: Jogailos st. 4, Vilnius. The Company has no branches or representative offices.The Company’s main activity is real estate development and construction. The Company owns a land plot and building complex in Vilnius, at Vasario 16 st. 1. The Company is developing a lyceum and hotel complex next to the Church and Monastery of the Apostles St. Philip and James. Highlights of the second quarter of 2025In April 2025, the historical part of the complex was registered as 100% completed. In April 2025, the Public Institution Modern School Center began operating in the complex. In June 2025, Reitan Convenience Lietuva and TNS Kantar began operating...

With its Omni-Channel Experience, CarMax Puts the Customer in the Driver’s SeatCarMax is Shaping the Future of Car Shopping with New “Wanna Drive?” Brand Positioning and TaglineWith its Omni-Channel Experience, CarMax Puts the Customer in the Driver’s SeatCarMax is Shaping the Future of Car Shopping with New “Wanna Drive?” Brand Positioning and TaglineWith its Omni-Channel Experience, CarMax Puts the Customer in the Driver’s SeatRICHMOND, VA, Aug. 25, 2025 (GLOBE NEWSWIRE) — CarMax, Inc. (NYSE: KMX), the nation’s largest retailer of used cars, is launching a new brand positioning, spotlighting its seamless, industry-leading omni-channel experience. After years of refining its model to allow customers to buy online, in-store or switch between the two effortlessly, CarMax is setting a new standard of the car-buying...

Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue Sarcoma DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. The company is advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited treatment options. The company’s lead compound, LB-100, is being evaluated in several investigator-led clinical studies aimed at enhancing the effectiveness of both chemotherapy and immunotherapy in treatment-resistant cancers. Microsatellite-Stable...

Vornado Realty Trust623 Fifth Avenue NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that it has entered into an agreement to purchase the 623 Fifth Avenue office condominium, a 36-story, 382,500 rentable square foot building situated above the flagship Saks Fifth Avenue department store, for $218 million. The building’s location provides for excellent light and air and sweeping, protected views of Midtown including Rockefeller Center and St. Patrick’s Cathedral. The building is currently 75% vacant and Vornado intends to completely reposition and redevelop it into a premier, best-in-class, Class A boutique office building. The fully transformed 623 Fifth Avenue building will complement Vornado’s nearby Plaza District and Park Avenue holdings of 280 Park Avenue, 350 Park Avenue, 595 Madison...

As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (“Agreement”) with Lupin Ltd and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Lupin’s Abbreviated New Drug Application (“ANDA”) seeking approval to market a generic version of FIRDAPSE® (amifampridine)...